A Phase 2b, Dose-Ranging Study of the Effect of GS-5745 on FEV1 in Adult Subjects With Cystic Fibrosis

Trial Profile

A Phase 2b, Dose-Ranging Study of the Effect of GS-5745 on FEV1 in Adult Subjects With Cystic Fibrosis

Discontinued
Phase of Trial: Phase II

Latest Information Update: 11 Oct 2017

At a glance

  • Drugs Andecaliximab (Primary)
  • Indications Cystic fibrosis
  • Focus Therapeutic Use
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 04 Aug 2017 This trial has been completed in Spain (on 2017-07-21), according to European Clinical Trials Database
    • 27 Jul 2017 Status changed from active, no longer recruiting to discontinued.
    • 16 Jun 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top